Quick Answer
Mineralys Therapeutics, Inc. reported Operating Income of -$170.60 million for fiscal year 2025.
Mineralys Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$170.60M | +11.3% |
| 2024 | -$192.40M | -127.3% |
| 2023 | -$84.66M | -168.9% |
| 2022 | -$31.48M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$41.13M | +31.6% | +12.0% |
| June 30, 2025 | -$46.75M | -3.5% | -5.2% |
| March 31, 2025 | -$44.45M | -25.7% | +26.1% |
| September 30, 2024 | -$60.11M | -128.8% | -33.1% |
| June 30, 2024 | -$45.17M | -187.1% | -27.7% |
| March 31, 2024 | -$35.36M | -136.7% | -34.6% |
| September 30, 2023 | -$26.27M | -253.9% | -67.0% |
| June 30, 2023 | -$15.73M | -142.9% | -5.3% |
- Mineralys Therapeutics, Inc. showed an increase of +11.3% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, Mineralys Therapeutics, Inc.’s operating income has declined by 442.0% (from -$31.48 million to -$170.60 million).
- The most recent figure is from Mineralys Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: